BR112023024231A2 - Células t primárias rhd negativas hipoimunogênicas - Google Patents

Células t primárias rhd negativas hipoimunogênicas

Info

Publication number
BR112023024231A2
BR112023024231A2 BR112023024231A BR112023024231A BR112023024231A2 BR 112023024231 A2 BR112023024231 A2 BR 112023024231A2 BR 112023024231 A BR112023024231 A BR 112023024231A BR 112023024231 A BR112023024231 A BR 112023024231A BR 112023024231 A2 BR112023024231 A2 BR 112023024231A2
Authority
BR
Brazil
Prior art keywords
cells
hypoimmunogenic
proteins
primary
rhd
Prior art date
Application number
BR112023024231A
Other languages
English (en)
Inventor
Sonja Schrepfer
Original Assignee
Sana Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sana Biotechnology Inc filed Critical Sana Biotechnology Inc
Publication of BR112023024231A2 publication Critical patent/BR112023024231A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

células t primárias rhd negativas hipoimunogênicas. são divulgadas neste documento células t hipoimunogênicas tendo expressão reduzida de antígeno de rhd para administração a um paciente. em algumas modalidades, as células são propagadas a partir de uma célula t primária ou uma progênie da mesma ou são derivadas de uma célula-tronco pluripotente induzida (ipsc). em algumas modalidades, as células expressam exogenamente proteínas de cd47 e exibem expressão reduzida de proteínas classe i de mhc, proteínas classe ii de mhc ou ambas. em algumas modalidades, as células expressam exogenamente um ou mais receptores de antígenos quiméricos.
BR112023024231A 2021-05-19 2022-05-20 Células t primárias rhd negativas hipoimunogênicas BR112023024231A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163190685P 2021-05-19 2021-05-19
US202163255803P 2021-10-14 2021-10-14
PCT/US2022/030394 WO2022246293A1 (en) 2021-05-19 2022-05-20 Hypoimmunogenic rhd negative primary t cells

Publications (1)

Publication Number Publication Date
BR112023024231A2 true BR112023024231A2 (pt) 2024-01-30

Family

ID=82703111

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024231A BR112023024231A2 (pt) 2021-05-19 2022-05-20 Células t primárias rhd negativas hipoimunogênicas

Country Status (6)

Country Link
EP (1) EP4340851A1 (pt)
AU (1) AU2022277931A1 (pt)
BR (1) BR112023024231A2 (pt)
CA (1) CA3219352A1 (pt)
IL (1) IL308637A (pt)
WO (1) WO2022246293A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023069790A1 (en) * 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
EP0970227B1 (en) 1997-03-20 2008-01-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
DE60236450D1 (de) 2001-09-26 2010-07-01 Us Health Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen
AU2004293471C1 (en) 2003-11-25 2011-02-24 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Mutated anti-CD22 antibodies and immunoconjugates
PL2406284T3 (pl) 2009-03-10 2017-09-29 Biogen Ma Inc. Przeciwciała anty-bcma
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
SG10201510092QA (en) 2010-12-09 2016-01-28 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
PL3415531T3 (pl) 2011-05-27 2024-02-26 Glaxo Group Limited Białka wiążące antygen
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
KR20180020125A (ko) 2015-03-27 2018-02-27 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 변형된 t 세포 및 이의 제조 및 사용 방법
US10968426B2 (en) 2015-05-08 2021-04-06 President And Fellows Of Harvard College Universal donor stem cells and related methods
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP2018534264A (ja) 2015-09-28 2018-11-22 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 自己免疫および同種免疫への治療的介入としてのキメラ抗原受容体（ｃａｒ）ｔ細胞
WO2017058753A1 (en) 2015-09-28 2017-04-06 Trustees Of Dartmouth College Chimeric antigen receptor, regulatory cells and methods of use
WO2018213337A1 (en) 2017-05-15 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
ES2928296T3 (es) 2017-06-30 2022-11-16 Us Health Receptores de antígenos quiméricos anti-antígenos de maduración de linfocitos B con dominios humanos
WO2019149269A1 (zh) 2018-02-01 2019-08-08 信达生物制药(苏州)有限公司 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
AU2019214163B2 (en) 2018-02-01 2021-06-24 Innovent Biologics (Suzhou) Co., Ltd. Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
WO2019149250A1 (zh) 2018-02-01 2019-08-08 南京驯鹿医疗技术有限公司 一种结合bcma的嵌合抗原受体(car)及其应用
KR20210032449A (ko) 2018-07-17 2021-03-24 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능성 줄기세포로부터 유래된 키메라 항원 수용체 t 세포
CA3138597A1 (en) * 2019-05-10 2020-11-19 The Regents Of The University Of California Modified pluripotent cells
CN116234906A (zh) * 2020-01-13 2023-06-06 萨那生物技术股份有限公司 血型抗原的修饰

Also Published As

Publication number Publication date
WO2022246293A1 (en) 2022-11-24
IL308637A (en) 2024-01-01
AU2022277931A1 (en) 2023-11-30
CA3219352A1 (en) 2022-11-24
EP4340851A1 (en) 2024-03-27
WO2022246293A8 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
CY1123299T1 (el) Ανοσοενισχυτικη μηνιγκιτιδοκοκκικη πρωτεϊνη προσδεσης παραγοντα η
Ginger et al. Intermediary metabolism in protists: a sequence-based view of facultative anaerobic metabolism in evolutionarily diverse eukaryotes
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
CY1118124T1 (el) Ανακατευθυνομενα, γενετικα τροποποιημενα ρυθμιστικα t-kyttapa και η χρηση τους στην καταστολη της αυτοανοσης και φλεγμονωδους ασθενειας
BR112023024231A2 (pt) Células t primárias rhd negativas hipoimunogênicas
PE20191324A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
Althaf et al. Human leukocyte antigen typing and crossmatch: A comprehensive review
CY1116365T1 (el) Στρωματικα βλαστικα κυτταρα
BRPI0410261A (pt) método de detecção de probnp natural
BR112021022757A2 (pt) Anticorpo anti-cldn e composição farmacêutica do mesmo e método de detecção para o mesmo
AR116048A1 (es) Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión
BR112022010179A2 (pt) Anticorpos anti-vírus da febre amarela, e métodos de sua geração e uso
BRPI0513596A (pt) anticorpo enriquecido para detecção de infecção micobacteriana, métodos de uso e teste diagnóstico empregando o mesmo
BR112023018844A2 (pt) Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas
AR069885A1 (es) Metodos para producir el virus de estomatitis vesicular (vsv) atenuado en un cultivo celular y para mejorar el empaque del vsv de propagacion defectuosa, composicion inmunogenica, celula aislada y secuencia de control transcripcional
BR112023002724A2 (pt) Neoantígenos ras e seus usos
BR112022005963A2 (pt) Células com expressão de transgenes sustentada
BR112023024434A2 (pt) Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas
BR112013032235A2 (pt) anticorpos do receptor de epo anti-humano e métodos de uso
Chang et al. Changes in circulating B cell subsets associated with aging and acute SIV infection in rhesus macaques
BR112016018826A8 (pt) anticorpo purificado, ou fragmento de ligação de antígeno, método para a identificação de uma população de células de esperma de mamífero portadoras de cromossomo x, e método in vitro para distorcer uma proporção entre os sexos
Laumaea et al. COVID‐19 vaccine humoral response in frequent platelet donors with plateletpheresis‐associated lymphopenia
BR112012019534A2 (pt) composição, métodos para preparar uma composição, e para selecionar anticorpos, e, kit
BR0307868A (pt) Estratégia para imunoterapia retroviral
BRPI0209172B8 (pt) método de detecção de doenças induzidas por glúten em uma amostra sanguínea de um indivíduo, e kit teste para uso no método